Comparing retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment Wednesday, June 14, 2023 NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours. The drug being studied is a new type of drug approved for the treatment of neuroendocrine tumours (NETs) that has been shown to shrink tumours in many people and seems promising, but it is not clear if receiving this drug again can offer better results than standard treatment. "This trial has the potential to be practice changing not only in Canada but around the world and we strongly believe this collaboration will improve the care of NETs patients worldwide, says Canadian Study Lead Dr. Simron Singh a medical oncologist at Sunnybrook Health Sciences Centre. This is a unique collaboration, a National Clinical Trials Network (NCTN) trial which was co-developed between CCTG with Dr Simron Singh and SWOG with Dr Aman Chauhan and a first from the NCI Gastroinstestinal Steering Committee that CCTG is leading. “The NET RETREAT trial is an excellent example of real collaboration between cooperative groups in taking an important trial concept from genesis through implementation across North America,” says Dr Chris O’Callaghan, CCTG Senior Investigator. “We look forward to its successful completion in addressing an important question for NET investigators and their patients." The study is currently enrolling patients at centres in Canada and the US. For more information, please visit the CCTG NE1 members trial page or the CCTG NE1 Patient trial information page. NET RETREAT Canadian Study Lead Dr Simron Singh Dr Chris O’Callaghan, CCTG Senior Investigator
